Market Place
Sourcing Support
Compugen Reports Q3 2024 Results
12 Nov 2024 //
PR NEWSWIRE
Compugen to Participate in Stifel 2024 Healthcare Conference
11 Nov 2024 //
PR NEWSWIRE
Compugen to Present COM701, COM902 + Pembrolizumab Data at SITC
05 Nov 2024 //
PR NEWSWIRE
Compugen To Release Q3 2024 Financial Results On Nov 12
29 Oct 2024 //
PR NEWSWIRE
Compugen to Present New Clinical Data at SITC 2024
07 Oct 2024 //
PR NEWSWIRE
Compugen to Present at Single Cell Genomics 2024 Conference
09 Sep 2024 //
PR NEWSWIRE
Compugen To Present At H.C. Wainwright Investment Conference
29 Aug 2024 //
PR NEWSWIRE
Compugen Reports Second Quarter 2024 Results
06 Aug 2024 //
PR NEWSWIRE
Compugen To Present At Antibody Industrial Symposium
17 Jun 2024 //
PR NEWSWIRE
Compugen Milestone On Dosing In Second Rilvegostomig Phase 3 Trial
30 May 2024 //
PR NEWSWIRE
Compugen, Nxera disclose milestone payments; Insmed aims for $650M offering
30 May 2024 //
ENDPTS
Compugen Reports First Quarter 2024 Results
20 May 2024 //
PR NEWSWIRE
Compugen Paper On PVRIG Biology, Therapeutic Potential
16 May 2024 //
PR NEWSWIRE
Compugen Appoints David Silberman as Chief Financial Officer
15 May 2024 //
PR NEWSWIRE
Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024
06 May 2024 //
PR NEWSWIRE
Compugen`s COM701 Triple Combo Shows Activity in mCRC at ASCO
25 Apr 2024 //
PR NEWSWIRE
Compugen Demonstrates Therapeutic Potential of COM503
10 Apr 2024 //
PR NEWSWIRE
Compugen to Participate in Two Upcoming Investor Conferences
03 Apr 2024 //
PR NEWSWIRE
Compugen Selected for Oral Presentations at Symposium on Cancer Immunotherapy
11 Mar 2024 //
PR NEWSWIRE
Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline
06 Mar 2024 //
PR NEWSWIRE
Compugen Reports Fourth Quarter and Full Year 2023 Results
05 Mar 2024 //
PR NEWSWIRE
Compugen to Present at the Leerink Partners Global Biopharma Conference 2024
26 Feb 2024 //
PR NEWSWIRE
Compugen to Release Fourth Quarter and Full Year 2023 Results
20 Feb 2024 //
PR NEWSWIRE
Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer
15 Feb 2024 //
PR NEWSWIRE
Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement
08 Jan 2024 //
PR NEWSWIRE
Gilead nabs rights to Compugen’s IL-18 immunotherapy programme
20 Dec 2023 //
PRESS RELEASE
Compugen Reports Third Quarter 2023 Results
07 Nov 2023 //
PR NEWSWIRE
Compugen`s COM701 (anti-PVRIG) Mediates Anti-Tumor Activity in Patients
06 Nov 2023 //
PR NEWSWIRE
Compugen Announces Receipt of Nasdaq Minimum Bid Price Notification
03 Nov 2023 //
PR NEWSWIRE
Compugen to Present New Data at SITC 2023
31 Oct 2023 //
PR NEWSWIRE
Compugen to Release Third Quarter 2023 Results on Tuesday, November 7, 2023
24 Oct 2023 //
PR NEWSWIRE
Compugen to Present at Single Cell Genomics 2023 Meeting
03 Oct 2023 //
PR NEWSWIRE
Compugen Expands Intellectual Property with New Japanese Patent
02 Oct 2023 //
PR NEWSWIRE
Compugen Reports Second Quarter 2023 Results
07 Aug 2023 //
PR NEWSWIRE
Compugen to Release Second Quarter 2023 Results on Monday, August 7, 2023
24 Jul 2023 //
PR NEWSWIRE
Compugen Wins on PVRIG EU Patent Opposition Pursued by GSK and a Third Party
17 Jul 2023 //
PR NEWSWIRE
Compugen Doses First Patient in Triple Immunotherapy Combination COM701, COM902
22 Jun 2023 //
PR NEWSWIRE
Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement
13 Jun 2023 //
PR NEWSWIRE
Compugen`s COM701 Demonstrates Preliminary Durable Anti-Tumor Activity
05 Jun 2023 //
PR NEWSWIRE
Compugen Reports First Quarter 2023 Results
15 May 2023 //
PR NEWSWIRE
Compugen to Host DNAM-1 Axis Virtual Investor Event with KOL Drew Pardoll
11 May 2023 //
PR NEWSWIRE
Compugen to Present at the JMP Securities Life Sciences Conference
09 May 2023 //
PR NEWSWIRE
Compugen to Present New Clinical Data Showing Anti-Tumor Activity of COM701
27 Apr 2023 //
PR NEWSWIRE
Compugen to Present Data on its Lead Pre-Clinical Asset COM503
26 Apr 2023 //
PR NEWSWIRE
Compugen to Present Study of Novel Target PVRIG at AACR 2023
15 Mar 2023 //
PR NEWSWIRE
Compugen to Participate in a Fireside Chat at Oppenheimer Healthcare Conference
08 Mar 2023 //
PR NEWSWIRE
Compugen Doses First Patient in Combination COM701, COM902 and Pembrolizumab
06 Mar 2023 //
PR NEWSWIRE
Compugen Reports Fourth Quarter and Full Year 2022 Results
27 Feb 2023 //
PR NEWSWIRE
Compugen to Release Fourth Quarter and Full Year 2022 Results on February 27
13 Feb 2023 //
PR NEWSWIRE
Compugen to Present at the SVB Securities Global Biopharma Conference
09 Feb 2023 //
PR NEWSWIRE
Compugen to Participate in the JMP Securities C-Suite Series
23 Jan 2023 //
PR NEWSWIRE
Compugen`s COM701 in Combination Demonstrates Durable Anti-Tumor Activity
06 Dec 2022 //
PRNEWSWIRE
Compugen touts ovarian cancer data in combo with Opdivo
06 Dec 2022 //
ENDPTS
Compugen to Participate in the JMP Securities Hematology and Oncology Summit
29 Nov 2022 //
PRESS RELEASE
Compugen to Receive Milestone Payment Triggered by AZ`s PD-1/TIGIT Bispecific
16 Nov 2022 //
PRESS RELEASE
Compugen Reports Third Quarter 2022 Results
14 Nov 2022 //
PRNEWSWIRE
Compugen to Participate in the Stifel Healthcare Conference
08 Nov 2022 //
PRESS RELEASE
Compugen`s COM701 Induces Potent Immune Activation in MSS-CRC Patients
07 Nov 2022 //
PRESS RELEASE
